Vector Science & Therapeutics Corp. (TSXV: PAIN) has announced the appointment of Darryl Drake Jr. as President of Valor and Chairman of the Athletic Board of Directors. Valor is a newly formed division of Vector, dedicated to building relationships within the professional and elite athlete market and establishing the commercial infrastructure to support Vector's advanced transdermal peptide delivery platform.
New Leadership for Market Development
Drake will lead Valor's market development efforts, initially promoting Vector's line of pharmaceutical-grade peptides. These peptides are manufactured under current Good Manufacturing Practice (cGMP) standards in an FDA-licensed facility and tested to the highest standards for safety and purity. He will also work to establish a network of sports medicine clinicians, trainers, and elite athlete advocates ahead of the commercial launch of the Valor transdermal delivery platform.
With over a decade of experience building high-performance commercial teams across multiple countries, Drake has a proven track record of managing relationships with top athlete influencers and multimedia-driven platforms. This positions him well for the relationship-first mandate that Valor requires.
Focus on Pharmaceutical-Grade Peptides
Valor's initial commercial focus is Vector's line of pharmaceutical-grade peptides, manufactured in a state-of-the-art facility in Mequon, Wisconsin. The division is designed to integrate Vector's advances in peptide science with its delivery platforms, creating a combined approach to tissue repair, recovery, and pain mitigation. This offers clinicians and athletes an alternative to systemic pain medicines, including opiates.
Drake understands the challenges of inadequate recovery options and the costs athletes face when pain is managed with systemic medications rather than targeted, site-directed intervention. His personal perspective, combined with his commercial track record and relationships across the athletic community, made him the ideal choice to lead Valor's market entry.
Statements from Leadership
"Athletes deserve better than systemic pain management and extended recovery timelines. Valor exists to change that, with precision delivery, targeted tissue repair, and solutions built for the way athletes actually heal," said Darryl Drake Jr., President of Valor.
"Darryl has the relationships, the track record, and the personal conviction this role demands. He is the right person to take Valor to market," added Bill Jackson, CEO of Vector Science & Therapeutics Corp.
About Darryl Drake Jr.
An early investor in Vector, Drake has spent over a decade building high-performance commercial teams responsible for more than $150 million in sales across multiple countries. He has consistently ranked in the top 1% of every organization he has been part of, demonstrating his ability to drive results and build strong networks.
